GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
  • 2
    In: Science of The Total Environment, Elsevier BV, Vol. 779 ( 2021-07), p. 146392-
    Type of Medium: Online Resource
    ISSN: 0048-9697
    RVK:
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2021
    detail.hit.zdb_id: 1498726-0
    detail.hit.zdb_id: 121506-1
    SSG: 12
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    In: Advances in Respiratory Medicine, MDPI AG, Vol. 81, No. 3 ( 2013-04-19), p. 200-206
    Abstract: Introduction: Dyspnoea and decreased exercise tolerance are symptoms of acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Anaemia is a risk factor for reduced functional capacity and dyspnoea in stable COPD. There is limited information about the impact of anaemia on functional capacity and dyspnoea of patients during AECOPD. The aim of this study was to evaluate the impact of decreased blood haemoglobin concentration on the results of six-minute walking test (6MWT) in patients during AECOPD. Material and methods: A post hoc analysis of data collected from prospective long-term studies on AECOPD. Haemoglobin concentration from the first obtainable hospital measurement were included in the assessment. 6MWT was performed after clinical improvement of the patient. Dyspnoea at baseline and after exercise and oxygen saturation (SpO2) during exercise was measured. Results: (presented as means ± SD): 402 patients with exacerbation of COPD (COPD stage 3.5 ± 0.6) were examined. Patients with anaemia (26% of those studied, age 74.5 ± 8.2 years) achieved 258.1 ± 125.1 m during 6MWT, with exertional desaturation of 2.9 ± 2.6%. Patients without anaemia (74% of those studied, age 70.2 ± 8.7 years) achieved 271 ± 136.0 m during 6MWT with exertional desaturation of 3.8 ± 3.7%. The haemoglobin concentration did not correlate with 6MWT, dyspnoea during 6MWT, or exercise oxygenation and blood desaturation during exercise. Conclusion: Mildly decreased blood haemoglobin concentration did not influence the results of 6MWT in patients with AECOPD.
    Type of Medium: Online Resource
    ISSN: 2543-6031
    Language: English
    Publisher: MDPI AG
    Publication Date: 2013
    detail.hit.zdb_id: 2893877-X
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    In: Advances in Respiratory Medicine, MDPI AG, Vol. 80, No. 5 ( 2012-08-27), p. 430-437
    Abstract: Introduction: Cardiac involvement in sarcoidosis is of critical importance, due to the poor prognosis if this organ manifesta- tion is left undiagnosed and untreated. The six-minute walk test (6 MWT) is a useful test to evaluate exercise tolerance of sarcoid patients. We aimed to assess the 6 MWT value in diagnosis, course and treatment monitoring of patients with cardiac sarcoidosis. Materials and methods: 47 patients were included: 22 with pulmonary sarcoidosis and cardiac involvement (13 women, 9 men), 25 with pulmonary sarcoidosis, with no changes in the heart (15 women, 10 men), and 18 healthy volunteers as controls (12 women, 6 men). Out of 22 patients with cardiac involvement 11 were treated for heart sarcoidosis with prednisone (9 pts—initial dose 60 mg daily and 2 pts—40 mg daily). 11 pts in this group were not treated. In all patients sarcoidosis was confirmed histopatologically. Magnetic resonance imaging was used to diagnose involvement of the heart. In the studied groups we assessed: heart rate (HR), oxygen saturation, distance in 6 MWT and Borg dyspnea score. Results: Patients with cardiac sarcoidosis desaturated more during exercise (DSaO2max = 3.5 ± 3.2 vs. 0.38 ± 0.69; p = 0.004) and had a lower increase of HR in first minute during the 6 MWT (DHR1 = 21.81 ± 11.72 vs. 50.61 ± 12.35; p = 0.0001) when compared to healthy subjects. Significantly lower increase of HR in first minute of 6 MWT was observed in patients with cardiac sarcoidosis when compared to patients with pulmonary sarcoidosis with no cardiac involvement (DHR1 = 21.81 ± 11.72 vs. 38.8 ± 18.17, p = 0.01). After introduction of treatment in sarcoidosis group, significantly higher (p = 0.02) increase of HR in first minute of 6 MWT as compared to baseline test was observed. Conclusions: The six-minute walk test is useful in diagnosing cardiac involvement in sarcoidosis. The increase in HR during exercise and decrease degree of desaturation were a good predictors of the response to therapy.
    Type of Medium: Online Resource
    ISSN: 2543-6031
    Language: English
    Publisher: MDPI AG
    Publication Date: 2012
    detail.hit.zdb_id: 2893877-X
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    Online Resource
    Online Resource
    Ovid Technologies (Wolters Kluwer Health) ; 2017
    In:  Transplantation Vol. 101 ( 2017-08), p. S97-S98
    In: Transplantation, Ovid Technologies (Wolters Kluwer Health), Vol. 101 ( 2017-08), p. S97-S98
    Type of Medium: Online Resource
    ISSN: 0041-1337
    RVK:
    Language: English
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date: 2017
    detail.hit.zdb_id: 2035395-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 6
    In: Medicine, Ovid Technologies (Wolters Kluwer Health), Vol. 98, No. 47 ( 2019-11), p. e18037-
    Abstract: Dyspnea and exercise intolerance are usually attributed to pulmonary disease in sarcoidosis patients. However, cardiac involvement may also be responsible for these symptoms. Data regarding the impact of heart involvement on lung function in cardiac sarcoidosis (CS) is limited. The aim of study was to compare the results of pulmonary function tests (PFTs) in patients with and without heart involvement. We performed a retrospective analysis of PFTs in a group of sarcoidosis patients both with and without heart involvement evaluated by cardiovascular magnetic resonance (CMR) study. The study was performed in the period between May 2008 and April 2016. We included data of sarcoidosis patients who underwent testing for possible CS (including CMR study) at a national tertiary referral center for patients with interstitial lung diseases. All patients had histopathologicaly confirmed sarcoidosis and underwent standard evaluation with PFTs measurements including spirometry, plethysmography, lung transfer factor ( T L,CO ), and 6-minute walking test (6MWT) assessed using the most recent predicted values. We identified 255 sarcoidosis patients (93 women, age 42 ± 10.7 y): 103 with CS and 152 without CS (controls). CS patients had significantly lower left ventricular ejection fraction (LVEF; 56.9 ± 7.0 vs 60.4 ± 5.4, P   〈  .001). Any type of lung dysfunction was seen in 63% of CS patients compared with 31% in the controls ( P  = .005). Ventilatory disturbances (obstructive or restrictive pattern) and low T L,CO were more frequent in CS group (52% vs 23%, P   〈  .001 and 38% vs 18% P   〈  .01 respectively). CS (OR = 2.13, 95% CI: 1.11–4.07, P  = .02), stage of the disease (OR = 3.13, 95% CI: 1.4–7.0, P  = .006) and LVEF (coefficient = –0.068 ± 0.027, P  = .011) were independent factors associated with low FEV 1 but not low T L,CO . There was a significant correlation between LVEF and FEV 1 in CS group ( r  = 0.31, n  = 89, P  = .003). No significant difference in 6MWD between CS patients and controls was observed. Lung function impairment was more frequent in CS. Lower LVEF was associated with decreased values of FEV 1 . Relatively poor lung function may be an indication of cardiac sarcoidosis.
    Type of Medium: Online Resource
    ISSN: 0025-7974 , 1536-5964
    Language: English
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date: 2019
    detail.hit.zdb_id: 2049818-4
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 7
    Online Resource
    Online Resource
    Oxford University Press (OUP) ; 2020
    In:  Interactive CardioVascular and Thoracic Surgery Vol. 30, No. 4 ( 2020-04-01), p. 559-564
    In: Interactive CardioVascular and Thoracic Surgery, Oxford University Press (OUP), Vol. 30, No. 4 ( 2020-04-01), p. 559-564
    Abstract: OBJECTIVES The American College of Chest Physicians guidelines recommend low-technology exercise tests in the functional evaluation of patients with lung cancer considered for resectional surgery. However, the 6-min walk test (6MWT) is not included, because the data on its clinical value are inconsistent. Our goal was to evaluate the 6MWT in assessing the risk of cardiopulmonary complications in candidates for lung resection. METHODS We performed a retrospective assessment of clinical data and pulmonary function test results in 947 patients, mean age 65.3 (standard deviation 9.5) years, who underwent a single lobectomy for lung cancer. In 555 patients with predicted postoperative values ≤60%, the 6MWT was performed. The 6-min walking distance (6MWD) and the distance-saturation product (DSP), which is the product of the 6MWD in metres, and the lowest oxygen saturation registered during the test were assessed. RESULTS A total of 363 patients with predicted postoperative values & lt;60% and a 6MWT distance (6MWD) ≥400 m or DSP ≥ 350 m% had a lower rate of cardiopulmonary complications than patients with shorter 6MWD or lower DSP values [odds ratio (OR) 0.53, 95% confidence interval (CI) 0.35–0.81] and 0.47 (95% CI 0.30–0.73), respectively. This result was also true for patients with predicted postoperative values & lt;40%, ORs 0.33 (95% CI 0.14–0.79) and 0.25 (95% CI 0.10–0.61), respectively. CONCLUSIONS The 6MWT is useful in the assessment of operative risk in patients undergoing a single lobectomy for lung cancer. It helps to stratify the operative risk, which is lower in patients with 6MWD ≥400 m or DSP ≥350 m% than in patients with a shorter 6MWD or lower DSP values.
    Type of Medium: Online Resource
    ISSN: 1569-9285
    Language: English
    Publisher: Oxford University Press (OUP)
    Publication Date: 2020
    detail.hit.zdb_id: 2096257-5
    detail.hit.zdb_id: 3167862-2
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 8
    In: Advances in Respiratory Medicine, MDPI AG, Vol. 82, No. 6 ( 2014-10-22), p. 518-533
    Abstract: Wstęp: Kortykosteroidoterapia jest według aktualnych wytycznych WASOG/ATS/ERS leczeniem pierwszego rzutu u chorych na przewlekłą sarkoidozę. Jest to leczenie obarczone wysokim ryzykiem wystąpienia objawów ubocznych, które pogarszają rokowanie odległe. J ednocześnie nie ma pewności, że glikokortykosteroidy (GKS) modyfikują naturalny przebieg choroby. Celem pracy była ocena skuteczności i bezpieczeństwa leczenia metotreksatem (MTX) w monoterapii chorych na przewlekłą sarkoidozę płucną. Materiał i metody: Do leczenia zakwalifikowano 50 chorych na przewlekłą sarkoidozę płuc potwierdzoną badaniem histopatologicznym, 28 M i 22 K, w średnim wieku 45.55 ± 8.9 roku, ze średnim czasem trwania choroby do włączenia MTX wynoszącym 12.34 ± 20.49 roku. W latach 2004–2013 zastosowano u tych chorych MTX w monoterapii, w dawkach 10 mg lub 15 mg tygodniowo. Czterdziestu jeden pacjentów było wcześniej leczonych GKS. Wszyscy mieli wykonywane badania laboratoryjne, czynnościowe oraz radiologiczne układu oddechowego przed rozpoczęciem leczenia i w trakcie monitorowania skuteczności (co 6 miesięcy) oraz bezpieczeństwa terapii (co 4–6 tygodni). Do analizy statystycznej oceniającej skuteczność leczenia włączono 49 chorych. Na podstawie retrospektywnej analizy wyników badań czynnościowych (FEV1, FVC, TLC, DLCO) wykonanych na zakończenie leczenia, w porównaniu z wynikami badań czynności płuc przed podaniem MTX (poprawa o 10% w zakresie FEV1, FVC, TLC lub o 15% DLCO), wyodrębniono chorych, u których stwierdzono obiektywną, istotną poprawę wskaźników czynnościowych płuc po leczeniu (grupa “z obiektywną poprawą po leczeniu”). Wyniki: Okres leczenia wynosił od 6 do 24 miesięcy, średnio 60.75 ± 34.1 tygodnia. W całej grupie istotną poprawę po leczeniu MTX stwierdzono dla SaO2 min (%) (p = 0.043) oraz dla DSaO2 (%) (p = 0.048) ocenianej w czasie testu 6-minutowego marszu. Istotnie lepsze efekty leczenia uzyskano w grupie otrzymującej 15 mg MTX tygodniowo oraz u chorych, którzy otrzymali sumarycznie większą dawkę MTX podczas całej kuracji. Istotną statystycznie różnicę po 6 miesiącach leczenia między grupami leczonymi 15 mg v. 10 mg tygodniowo stwierdzono dla DLCO% pred (73.27 ± 12.7 vs. 63.15 ± 16.4; p = 0.03). Obiektywną poprawę po leczeniu stwierdzono u 25 pacjentów (55%). Chorzy, u których stwierdzono obiektywną poprawę po MTX, mieli wyjściowo istotnie niższe wartości TLC i FVC w porównaniu z grupą bez poprawy po MTX. Po zakończeniu leczenia jedyną istotnie statystycznie różnicę między obiema grupami obserwowano w zakresie DLCO. U 11 chorych (22%) przerwano leczenie z powodu objawów ubocznych. Najczęściej obserwowanym objawem ubocznym leczenia był wzrost wskaźników wątrobowych (10 chorych, 20%). U 4 osób stwierdzono powikłania infekcyjne. U żadnego chorego nie stwierdzono powikłań zagrażających życiu. Wnioski: Metotreksat w monoterapii może być bezpieczną i skuteczną alternatywą dla steroidów. U części chorych należy spodziewać się obiektywnej poprawy czynności płuc po leczeniu. Wskazane są dalsze badania w poszukiwaniu wskaźników prognozujących skuteczność leczenia.
    Type of Medium: Online Resource
    ISSN: 2543-6031
    Language: English
    Publisher: MDPI AG
    Publication Date: 2014
    detail.hit.zdb_id: 2893877-X
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...